BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 8099637)

  • 1. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group.
    Modlin JF; Halsey NA; Thoms ML; Meschievitz CK; Patriarca PA
    J Infect Dis; 1997 Feb; 175 Suppl 1():S228-34. PubMed ID: 9203721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya.
    Kok PW; Leeuwenburg J; Tukei P; van Wezel AL; Kapsenberg JG; van Steenis G; Galazka A; Robertson SE; Robinson D
    Bull World Health Organ; 1992; 70(1):93-103. PubMed ID: 1568283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
    Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
    Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
    Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
    Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
    Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
    Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman.
    Sutter RW; Suleiman AJ; Malankar PG; Mehta FR; Medany MA; Arif MA; Linkins RW; Pallansch MA; El-Bualy MS; Robertson SE
    J Infect Dis; 1997 Feb; 175 Suppl 1():S235-40. PubMed ID: 9203722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].
    Lu L; Li XM; Liu DL; Zhang HR; Zhang ZJ; Wang HH; Liu F; Ning ZQ; Zhang LW; Chu P; Xie YT; Xu Y; Li J; Pang XH; Deng Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):510-3. PubMed ID: 22943896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine or live oral poliovirus vaccine.
    Modlin JF; Onorato IM; McBean AM; Albrecht P; Thoms ML; Nerhood L; Bernier R
    Am J Dis Child; 1990 Apr; 144(4):480-4. PubMed ID: 2157337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
    Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?
    Ogra PL
    Public Health Rev; 1993-1994; 21(1-2):143-50. PubMed ID: 8041881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
    Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
    Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of a supplemental dose of four poliovirus vaccines.
    Sutter RW; Suleiman AJ; Malankar P; Al-Khusaiby S; Mehta F; Clements GB; Pallansch MA; Robertson SE
    N Engl J Med; 2000 Sep; 343(11):767-73. PubMed ID: 10984564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.